Benitec Biopharma
BNTC
5 hedge funds and large institutions have $1.05M invested in Benitec Biopharma in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.
464% more capital invested
Capital invested by funds: $186K → $1.05M (+$863K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
29% less funds holding
Funds holding: 7 → 5 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$984K |
| 2 |
VF
Virtu Financial
New York
|
+$8.09K |
| 3 |
Morgan Stanley
New York
|
+$6.43K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$368 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$55K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$30K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24K |
| 4 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $971K | +$984K | +5,355 | New |
|
|
2
Morgan Stanley
New York
| $56K | +$6.43K | +35 | +13% |
|
3
Renaissance Technologies
New York
| $10K | – | – | – |
|
|
VF
4
Virtu Financial
New York
| $8K | +$8.09K | +44 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $4K | +$368 | +2 | +9% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$55K | -291 | Closed |
|
|
SFM
7
Sphera Funds Management
Tel Aviv,
Israel
| – | -$30K | -157 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$24K | -128 | Closed |
|
|
OMC
9
Old Mission Capital
Chicago,
Illinois
| – | -$10K | -51 | Closed |
|
BNTC Hedge Fund Activity: Q3 2019 in Review
5 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2019, worth a combined $1.05M — up 464% from $186K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BNTC and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $984K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $55K sold.
- 5 institutional investors held Benitec Biopharma (BNTC) as of Q3 2019, down from 7 in Q2 2019.
- Funds reported $1.05M of Benitec Biopharma stock for Q3 2019, up 464% quarter-over-quarter.
- 2 funds opened new Benitec Biopharma positions in Q3 2019 and 4 closed out, a net change of -2 holders.
- The largest Benitec Biopharma buyer in Q3 2019 was Sabby Management, an estimated $984K added.
- The largest Benitec Biopharma seller in Q3 2019 was Susquehanna International Group, an estimated $55K sold.
Based on aggregated 13F filings for Q3 2019.